Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 May 15;88(10):4523-7.
doi: 10.1073/pnas.88.10.4523.

Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse

Affiliations

Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse

H Kaneshima et al. Proc Natl Acad Sci U S A. .

Abstract

The SCID-hu mouse is a small animal in which human hematolymphoid organs can be engrafted and maintained in vivo. In this study, parameters are described for reproducible infection of SCID-hu mice after i.v. inoculation. Infection was found to be dependent upon the time after inoculation, the virus isolate, the titer of virus, and the human target organ implanted into the mouse. Ten to 14 days after the i.v. administration of HIV isolates derived freshly from patients (e.g., JR-CSF, JR-FL, SM), 100% of engrafted human lymph nodes in SCID-hu mice were infected; greater than 95% of these animals were also viremic. Implants of human thymus or connective tissue, as well as the endogenous murine hematolymphoid organs, were not infected. As demonstrated by a combination of in situ hybridization and immunohistochemistry, both T-lymphoid and myelomonocytic lineage cells were infected in this system. HIV isolates that have been adapted to growth in vitro (e.g., HTLV-IIIb) were not infectious. When either 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxyinosine (ddIno) was administered to SCID-hu mice before HIV infection, the animals were protected in dose ranges similar to those used in man. This animal model may now be used as an efficient intermediate step between the lab and the clinic to study the infectious process in vivo and to best select efficacious antiviral compounds against HIV.

PubMed Disclaimer

References

    1. N Engl J Med. 1987 Jul 23;317(4):185-91 - PubMed
    1. Cancer Chemother Rep. 1966 May;50(4):219-44 - PubMed
    1. Science. 1986 Jul 11;233(4760):215-9 - PubMed
    1. Science. 1986 Sep 5;233(4768):1089-93 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 - PubMed

Publication types

MeSH terms